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Activins are members of the transforming growth factor
b (TGFb) family of growth and differentiation factors
(1). Like the other members of this family, they consist of
dimers of glycosylated polypeptides, linked by a disulfide
bond. To date, five different forms (A to E) of the activin
subunit have been described on the basis of nucleotide
sequences. However, biological activities have only been
described for three of them: activins A, B and AB, the
last being a heterodimer of the A and B form.
In common with TGFb and its other family members,
which include the bone morphogenetic proteins, the
growth and differentiation factors and anti-Mu¨llerian
hormone, activins act by binding to members of a family
of transmembrane receptors (1). These receptors consist
of an extracellular domain, which can interact with the
ligand, a transmembrane domain, and an intracellular
domain, which can phosphorylate other proteins on
serine or threonine residues. When activin is bound to
the receptor, which is itself constitutively activated by
phosphorylation, a second serine-threonine kinase can
be recruited into this complex. Cross-linking experi-
ments indicated the formation of a complex, in which
interaction between ligand and both kinases occurs;
for this reason the second kinase is also regarded as a
receptor. On the basis of apparent molecular weight, the
latter, smaller receptor is called the type I receptor,
whereas the former, larger ligand-binding molecule is
designated the type II receptor.
The type I receptor is activated by phosphorylation
by the type II receptor, and itself phosphorylates a
member of a family of intracellular signal transduction
proteins, the so-called ‘SMADs’ (2), which can convey the
signal to the nucleus. For activin, two subtypes of each of
the receptors have been described: IIA and IIB and IA and
IB.
The action of activin can be prohibited in two ways:
the activin-binding protein, follistatin, can bind to the
activin subunit and prevent the interaction of activin
with its type II receptors (3) or, alternatively, the actions
of activin can be counteracted by inhibin, a heterodimer
of an activin subunit with a distantly related family
member, the inhibin a-subunit. Because inhibin was
characterized before activin, the activin subunit was
earlier defined as the inhibin b-subunit; inhibin might
act by binding to type II activin receptors, through this
common b-subunit. Binding of inhibin to the IIB
receptor appears to be more effective than binding to
the IIA receptor (4), and this differential binding of
inhibin might explain why some actions of activin can
be blocked by inhibin, whereas other can not. Follistatin,
in contrast, should block the actions of activin through
type IIA and IIB receptors with similar effectiveness.
The Sertoli cells in the testicular seminiferous tubules
produce inhibin, which is subsequently secreted and
suppresses the production of follicle stimulating hormone
(FSH) in the pituitary gland. It is likely that this action is
caused by the above-described activin-antagonizing
action of inhibin; activin stimulates FSH production
and is locally produced by pituitary gonadotrophs (5).
Because FSH can stimulate inhibin production by the
testis, the activin–FSH–inhibin system is a closed feed-
back loop, which has a role in the regulation of the
function of the seminiferous tubules, i.e. the production
of spermatozoa. Recent evidence, however, indicates that
spermatogenesis may proceed even in the absence of FSH
(6).
A more direct level of involvement of the activin/
inhibin system in the regulation of spermatogenesis
may be at the level of the spermatogenic cells themselves.
Activin is produced by Sertoli and peritubular cells (7, 8),
and activin receptors are present in almost any testicular
cell type: Leydig and Sertoli cells contain activin receptors
(ActR) type IIA (9, 10), whereas the early spermatogenic
cells – the spermatogonia – contain ActRIIB (11), and
the further-developed cells – spermatocytes and sperma-
tids – express ActRIIA (9, 10). Presence of type I
receptors in spermatogenic cells has also been reported
recently; from a study on the ontogeny of type I receptors,
it appears that spermatids express the mRNA encoding
activin receptor type IB (12).
Of course, the presence of the ligand and the receptors
does not prove that there is an effect of activin on
spermatogenesis. However, from the studies of Mather
et al. (13), it appears that in vitro addition of activin to
spermatogonia increases their mitotic activity. In con-
trast, inhibin can suppress the numbers of intermediate
and late spermatogonia after intratesticular injection
in vivo. This might be explained on basis of the presence
of activin IIB receptors in spermatogonia (14). The role
of inhibin in blocking the action of activin at the activin
receptor type IIA in spermatocytes and early spermatids is
less clear; as stated above, the potency to antagonize the
action of activin at this receptor is less than that at the
activin receptor type IIB. However, in a paper in this issue
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of the European Journal of Endocrinology (15), it is indicated
that the immunoreactivity of follistatin increases in these
spermatogenic cell types. For the pituitary gland and the
ovary it is known that activin is able to stimulate the
production of follistatin (16, 17), leading to a diminished
activity of activin itself; in the spermatogenic cells, a
similar mechanism might play a part.
Production of follistatin in cultures of Sertoli cells has
been described (18). Follistatin mRNA is localized in
Sertoli cells, but not in spermatogenic cells (9). Finally,
follistatin was detected by immunocytochemistry in
Sertoli cells, and mainly in Leydig cells (19). It is difficult
to combine these conflicting data on localization of
follistatin in one concept of the production and action
of follistatin. The only reasonable explanation might
be to postulate uptake of follistatin, together with
activin, by the spermatogenic cell types that express
activin receptor IIA. Such a mechanism can exist only
if a follistatin–activin subunit–activin subunit–activin
receptor type II complex could be imported into the cell;
in this way interaction with the type I receptor can be
prevented.
In this context, it is interesting to note that
spermatogenesis itself can affect the expression of the
subunits necessary for the production of activin or
inhibin (20). By changing the ratio between a- and
b-subunit expression, the ratio between the amounts of
agonist and antagonist produced can be affected. If the
hypothesis of activin-induced production of follistatin is
true, the amount of activin that is not counteracted by
inhibin would subsequently lead to production or
import of an amount of follistatin, which would further
fine-tune the activin signal in the complex process of
spermatogenesis.
In summary, testicular cells are protected against
activin by several mechanisms. Deletion of one of these
mechanisms by deletion of the inhibin a-subunit gene
leads to tumorigenesis of Sertoli cells (21). Follistatin
may be another molecule that potects testicular cells
against this ‘hot’ molecule. Unfortunately, it will be
difficult to prove this hypothesis, as results of follistatin
gene knock-out experiments indicate that this deletion
leads to early postnatal death (22).
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